These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26232000)

  • 21. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
    Lambert-Niclot S; Allavena C; Grude M; Flandre P; Sayon S; Andre E; Wirden M; Rodallec A; Jovelin T; Katlama C; Calvez V; Raffi F; Marcelin AG
    J Antimicrob Chemother; 2016 Aug; 71(8):2248-51. PubMed ID: 27231280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switch as maintenance to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate: week 48 results in a clinical cohort.
    Perrier M; Charpentier C; Peytavin G; Lê M; Blondel L; Visseaux B; Joly V; Pinto A; Matheron S; Yazdanpanah Y; Descamps D; Landman R
    J Antimicrob Chemother; 2017 Jun; 72(6):1745-1751. PubMed ID: 28186251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.
    Palacios R; Mayorga M; Pérez-Hernández IA; Rivero A; Arco AD; Lozano F; Santos J;
    J Int Assoc Provid AIDS Care; 2016 May; 15(3):189-93. PubMed ID: 26858314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants.
    Palella FJ; Fisher M; Tebas P; Gazzard B; Ruane P; Van Lunzen J; Shamblaw D; Flamm J; Ebrahimi R; Porter D; White K; Hindman J; Elbert E; De-Oertel S; Fralich T
    AIDS; 2014 Jan; 28(3):335-44. PubMed ID: 24670520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
    Gantner P; Reinhart S; Partisani M; Baldeyrou M; Batard ML; Bernard-Henry C; Cheneau C; de Mautort E; Priester M; Fafi-Kremer S; Muret P; Rey D
    HIV Med; 2015 Feb; 16(2):132-6. PubMed ID: 25124291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine.
    Vélez-Díaz-Pallarés M; Gramage-Caro T; Rodríguez-Sagrado MÁ; Montero-Llorente B; Bermejo-Vicedo T
    Biomedica; 2020 May; 40(Supl. 1):132-138. PubMed ID: 32463615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
    Troya J; Ryan P; Ribera E; Podzamczer D; Hontañón V; Terrón JA; Boix V; Moreno S; Barrufet P; Castaño M; Carrero A; Galindo MJ; Suárez-Lozano I; Knobel H; Raffo M; Solís J; Yllescas M; Esteban H; González-García J; Berenguer J; Imaz A;
    PLoS One; 2016; 11(10):e0164455. PubMed ID: 27727331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
    Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
    AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switch to Rilpivirine/Emtricitabine/Tenofovir Single-Tablet Regimen of Human Immunodeficiency Virus-1 RNA-Suppressed Patients, Agence Nationale de Recherches sur le SIDA et les Hépatites Virales CO3 Aquitaine Cohort, 2012-2014.
    Cazanave C; Reigadas S; Mazubert C; Bellecave P; Hessamfar M; Le Marec F; Lazaro E; Peytavin G; Bruyand M; Fleury H; Dabis F; Neau D
    Open Forum Infect Dis; 2015 Jan; 2(1):ofv018. PubMed ID: 26034768
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
    Lewis JM; Smith C; Torkington A; Davies C; Ahmad S; Tomkins A; Shaw J; Kingston M; Muqbill G; Hay P; Mulka L; Williams D; Waters L; Brima N; Marshall N; Johnson M; Chaponda M; Nelson M
    J Infect; 2017 Apr; 74(4):401-407. PubMed ID: 28143756
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, efficacy, and pharmacokinetics of single-tablet elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in virologically suppressed, HIV-infected children: a single-arm, open-label trial.
    Natukunda E; Gaur AH; Kosalaraksa P; Batra J; Rakhmanina N; Porter D; Shao Y; Zhang H; Pikora C; Rhee MS
    Lancet Child Adolesc Health; 2017 Sep; 1(1):27-34. PubMed ID: 30169223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
    Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
    Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Effectiveness of Rilpivirine-Based Single-Tablet Regimens in a Seven-Year, Two-Center Observational Cohort of People Living with HIV.
    Taramasso L; Lo Caputo S; Magnasco L; Briano F; Poliseno M; Bruno SR; Ferrara S; Pincino R; Sarteschi G; Beltramini S; Sasso E; Mora S; Giacomini M; Bassetti M; Di Biagio A
    AIDS Res Hum Retroviruses; 2022 Jun; 38(6):472-479. PubMed ID: 35172617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.
    Rotzinger A; Locatelli I; Bugnon O; Fayet Mello A; Parienti JJ; Cavassini M; Schneider MP
    HIV Med; 2016 May; 17(5):390-6. PubMed ID: 26688004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans.
    Collins SE; Grant PM; Uwinkindi F; Talbot A; Seruyange E; Slamowitz D; Mugeni A; Remera E; Niyonsenga SP; Nyirimigabo J; Uwizihiwe JP; Dongier P; Muhayimpundu R; Mazarati JB; Zolopa A; Nsanzimana S
    Open Forum Infect Dis; 2016 Sep; 3(3):ofw141. PubMed ID: 27704000
    [No Abstract]   [Full Text] [Related]  

  • 37. Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice.
    Ranzenigo M; Gianotti N; Galli L; Poli A; Mastrangelo A; Bruzzesi E; Chiurlo M; Nozza S; Bossolasco S; Spagnuolo V; Mancusi D; Termini R; Carini E; Lazzarin A; Castagna A
    Drug Des Devel Ther; 2022; 16():1975-1982. PubMed ID: 35783200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
    Naicker N; Naidoo A; Werner L; Garrett N; Majola N; Asari V; Baxter C; Grobler A; Karim QA; Karim SSA
    Antivir Ther; 2017; 22(4):287-293. PubMed ID: 27835613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
    Porter DP; Toma J; Tan Y; Solberg O; Cai S; Kulkarni R; Andreatta K; Lie Y; Chuck SK; Palella F; Miller MD; White KL
    HIV Clin Trials; 2016 Feb; 17(1):29-37. PubMed ID: 26899540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral blips were infrequent in treatment-naive adults treated with rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF through 96 weeks.
    Porter DP; Kulkarni R; Garner W; Miller MD; White KL
    Antivir Ther; 2017; 22(6):495-502. PubMed ID: 28091393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.